{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:10:49Z","timestamp":1795173049679,"version":"4.10.3"},"reference-count":68,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,12,13]],"date-time":"2017-12-13T00:00:00Z","timestamp":1513123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.clml.2017.11.006","type":"journal-article","created":{"date-parts":[[2017,11,29]],"date-time":"2017-11-29T17:48:50Z","timestamp":1511977730000},"page":"98-105","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"18","author":[{"given":"Stuart L.","family":"Goldberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.11.006_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib2","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.clml.2017.11.006_bib3","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.006_bib4","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40291-015-0139-2","article-title":"Technical issues behind molecular monitoring in chronic myeloid leukemia","volume":"19","author":"Mattarucchi","year":"2015","journal-title":"Mol Diagn Ther"},{"key":"10.1016\/j.clml.2017.11.006_bib6","article-title":"Impact of treatment with frontline nilotinib (NIL) vs imatinib (IM) on sustained deep molecular response (MR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP)","volume":"126","author":"Hochhaus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib9","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-term follow-up of the French Stop Imatinib study (STIM1) in chronic myeloid leukemia patients","volume":"35","author":"Etienne","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib10","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.654.654","article-title":"Preliminary report of the STIM2 study: a multicenter Stop Imatinib Trial for chronic phase chronic myeloid leukemia de novo patients on imatinib","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib11","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2012.48.5797","article-title":"Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib12","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER Study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3324\/haematol.2015.139899","article-title":"Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study","volume":"101","author":"Lee","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib14","article-title":"Late relapses, up to 45 months after imatinib discontinuation: results from the ISAV study","volume":"101","author":"Mori","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib15","article-title":"Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial","volume":"101","author":"Richter","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib16","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1182\/blood-2016-09-742205","article-title":"France Intergroupe des Leucemies Myeloides Chroniques. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study","volume":"129","author":"Rea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib17","doi-asserted-by":"crossref","first-page":"e528","DOI":"10.1016\/S2352-3026(15)00196-9","article-title":"Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial","volume":"2","author":"Imagawa","year":"2015","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2017.11.006_bib18","article-title":"Attempt to early discontinue dasatinib first line in chronic phase CML patients in early molecular response and included in the prospective OPTIM-dasatinib trial","volume":"100","author":"Rousselot","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib19","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/leu.2017.63","article-title":"Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study","volume":"31","author":"Hochhaus","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.006_bib20","article-title":"Results from ENESTop: treatment-free remission following switch to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"101","author":"Hughes","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib21","article-title":"Successful treatment free remission in CML after 2 year consolidation with nilotinib of an MR4.5 response level achieved original with imatinib treatment: first report from STAT2 trial in Japan","volume":"101","author":"Takahashi","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.790.790","article-title":"Discontinuation of nilotinib in patients with chronic myeloid leukemia who have maintained deep molecular responses for at least 2 years: a multicenter phase 2 Stop Nilotinib (NILSt) trial","volume":"128","author":"Kadowaki","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib23","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1895.1895","article-title":"Treatment-free remission (TFR) in patients with chronic phase chronic myeloid leukemia (CML-CP) and in stable deep molecular response (DMR) to dasatinib - the DASFREE Study","volume":"128","author":"Shah","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib24","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.791.791","article-title":"Discontinuation of dasatinib after deep molecular response for over 2 years in patients with chronic myelogenous leukemia and the unique profiles of lymphocyte subsets for successful discontinuation: a prospective, multicenter Japanese trial (D-STOP Trial)","volume":"128","author":"Kumagai","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2014.32.15_suppl.tps7124","article-title":"Treatment-free remission (TFR) following nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath","volume":"32","author":"Mahon","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood-2016-01-694265","article-title":"Moving treatment-free remission into mainstream clinical practice in CML","volume":"128","author":"Hughes","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib27","article-title":"Efficacy and safety of nilotinib vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase: 6-year follow-up of ENESTnd","volume":"100","author":"Hughes","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib28","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","article-title":"Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-Study IV","volume":"32","author":"Hehlmann","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib29","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1182\/blood-2008-06-161737","article-title":"Impact of early dose intensity on cytogenetic and molecular responses in chronic-phase CML patients receiving 600 mg\/day of imatinib as initial therapy","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1182\/blood-2014-07-590315","article-title":"TIDEL-II: frontline use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets","volume":"125","author":"Yeung","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib31","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1038\/leu.2017.247","article-title":"Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results","volume":"31","author":"Hughes","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.006_bib32","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A\u00a0phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2017.11.006_bib33","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/ajh.23788","article-title":"Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.006_bib34","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.1016\/S2352-3026(17)30066-2","article-title":"De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial","volume":"4","author":"Clark","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2017.11.006_bib35","article-title":"Initial reduction of therapy before complete withdrawal improves the chance of successful treatment discontinuation in chronic myeloid leukaemia (CML): year 2 results in the British DESTINY study","volume":"102","author":"Clark","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3090.3090","article-title":"ENESTgoal treatment-free remission study: updated preliminary results and digital polymerase chain reaction analysis in patients with chronic myeloid leukemia in chronic phase who switched from imatinib to nilotinib","volume":"128","author":"Ritchie","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib38","article-title":"Treatment-Free Remission Accomplished By Dasatinib (TRAD): preliminary results of the pan-Canadian tyrosine kinase inhibitor discontinuation trial","volume":"128","author":"Kim","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib39","article-title":"Durable treatment-free remission (TFR) following frontline nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTfreedom 96-wk update","volume":"102","author":"Ross","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib40","article-title":"Durable treatment-free remission (TFR) after stopping second-line nilotinib (NIL) in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): ENESTop 96-wk update","volume":"102","author":"Hughes","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib41","article-title":"Final study results of discontinuation of dasatinib in patients with CML who maintained deep molecular response for longer than one year (DADI trial) after three years of follow-up","volume":"102","author":"Nakamae","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib42","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.leukres.2015.07.004","article-title":"Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients","volume":"39","author":"Breccia","year":"2015","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.11.006_bib43","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.4547.4547","article-title":"Attitudes and\u00a0perceptions of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) toward treatment-free remission (TFR)","volume":"124","author":"Boquimpani","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib44","article-title":"Patients with chronic myelogenous leukemia may not want to discontinue tyrosine kinase inhibitor therapy","volume":"126","author":"Goldberg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib45","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.3747\/co.21.1736","article-title":"Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"21","author":"Sanford","year":"2014","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib46","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s00432-016-2159-7","article-title":"Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia","volume":"142","author":"Jiang","year":"2016","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib47","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.leukres.2013.07.003","article-title":"Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors","volume":"38","author":"Efficace","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.11.006_bib48","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2775.2775","article-title":"Imatinib suspension and validation study: results at 24 months","volume":"126","author":"Mori","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib50","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1200\/JCO.2014.55.6910","article-title":"Musculoskeletal pain in patients with chronic myeloid leukemia after discontinuation of imatinib: a tyrosine kinase inhibitor withdrawal syndrome?","volume":"32","author":"Richter","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib51","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2014.56.3858","article-title":"Reply to J. Richter et\u00a0al","volume":"32","author":"Rousselot","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib52","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/10428194.2015.1049166","article-title":"Change of health-related profiles after imatinib cessation in chronic phase chronic myeloid leukemia patients","volume":"57","author":"Park","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.006_bib53","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.1585.1585","article-title":"Age and cost are associated with patient preference for stopping tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"126","author":"Jiang","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.255.255","article-title":"Long term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study","volume":"122","author":"Mahon","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5168.5168","article-title":"A\u00a0single institution respective study of tyrosine kinase inhibitor cessation in patients with chronic phase CML in MMR","volume":"126","author":"McCloskey","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.5161.5161","article-title":"Economic impact of imatinib mesylate withdraw: as option for third world countries?","volume":"126","author":"Burin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib57","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ajh.24120","article-title":"Age and dPCR can predict relapse in CML patients who discontinued imatinib: the ISAV study","volume":"90","author":"Mori","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.006_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.1889.1889","article-title":"Two-year consolidation by nilotinib is associated with successful treatment free remission in chronic myeloid leukemia with MR: subgroup analysis from STAT2 trial in Japan","volume":"128","author":"Takahashi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib59","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/ajh.23427","article-title":"Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib","volume":"88","author":"Lee","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.006_bib60","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3324\/haematol.2011.056853","article-title":"Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia","volume":"97","author":"Takahashi","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13045-016-0293-y","article-title":"Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients","volume":"9","author":"Caocci","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.11.006_bib62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.006_bib63","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3324\/haematol.2017.165001","article-title":"Natural killer cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study","volume":"102","author":"Rea","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.006_bib64","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.11.006_bib65","doi-asserted-by":"crossref","first-page":"e28861","DOI":"10.4161\/onci.28861","article-title":"Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse","volume":"3","author":"Yoshimoto","year":"2014","journal-title":"OncoImmunology"},{"key":"10.1016\/j.clml.2017.11.006_bib66","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.exphem.2015.08.004","article-title":"Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients","volume":"43","author":"Caocci","year":"2015","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2017.11.006_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.599.599","article-title":"Frequency of CTLA-4 receptor ligand (CD86, B7.2)-positive plasmacytoid dendritic cells predicts risk of disease recurrence after tyrosine-kinase inhibitor discontinuation in chronic myeloid leukemia: results from a prospective substudy of the EUROSKI trial","volume":"126","author":"Burchert","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.006_bib68","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.24362","article-title":"Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia","volume":"91","author":"Gugliotta","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.006_bib69","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.788.788","article-title":"Second TKI discontinuation in CML patients that failed first discontinuation and subsequently regained deep molecular response after TKI re-challenge","volume":"128","author":"Pagliardini","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017309916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:44Z","timestamp":1761870584000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017309916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":68,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S2152265017309916"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Considerations for Successful Treatment-free Remission in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}